A PHASE 2 RANDOMIZED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MYOSTATIN ANTIBODY LY2495655 VERSUS PLACEBO IN PATIENTS UNDERGOING ELECTIVE TOTAL HIP ARTHROPLASTY
The DOI matches its Crossref record.
Abstract
Background: Total hip arthroplasty relieves joint pain in patients with end stage osteoarthritis. However, postoperative muscle atrophy often results in suboptimal lower limb function. There is a need to improve functional recovery after total hip arthroplasty. Objectives: To assess safety and efficacy of LY2495655, a humanized monoclonal antibody targeting myostatin, in patients undergoing elective total hip arthroplasty. Design: Phase 2, randomized, parallel, double-blind, 12-week clinical trial with a 12-week follow-up period. Setting: Forty-two sites in 11 countries. Participants: Individuals (N=400) aged ≥50 years scheduled for elective total hip arthroplasty for osteoarthritis within 10 ± 6 days after randomization. Intervention: Placebo or LY2495655 (35 mg, 105 mg, or 315 mg) subcutaneous injections at weeks 0 (randomization date), 4, 8, and 12 with follow up until week 24. Measurements: Primary endpoint: probability that LY2495655 increases appendicular lean mass (operated limb excluded) by at least 2.5% more than placebo at week 12, using dual-energy x-ray absorptiometry. Exploratory endpoints: muscle strength, performance based and self-reported measures of physical function, and whole body composition over time. Results: Participants: 59% women, aged 69 ± 8 years, BMI 29 ± 5 kg/m2. Groups were comparable at baseline. The primary objective was not reached as LY2495655 changes in lean mass did not meet the superiority threshold at week 12. However, LY2495655 105 and LY2495655 315 experienced progressive increases in appendicular lean mass that were statistically significant versus placebo at weeks 8 and 16. Whole body fat mass decreased in LY2495655 315 versus placebo at weeks 8 and 16. No meaningful differences were detected between groups in other exploratory endpoints. Injection site reactions occurred more often in LY2495655 patients than in placebo patients. No other safety signals were detected. Conclusion: Dose-dependent increases in appendicular lean body mass and decreases in fat mass were observed, although this study did not achieve the threshold of its primary objective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sarcopenia in chronic kidney disease: what have we learned so far?
Sabatino, A., Cuppari, L., Stenvinkel, P., Lindholm, B., & Avesani, C. M. (2021) · Journal of Nephrology · doi:10.1007/s40620-020-00840-y · Cited by 507
Muscle wasting and cachexia in heart failure: mechanisms and therapies
von Haehling, S., Ebner, N., dos Santos, M. R., Springer, J., & Anker, S. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.51 · Cited by 421
A review of sarcopenia: Enhancing awareness of an increasingly prevalent disease
Marty, E., Liu, Y., Samuel, A., Or, O., & Lane, J. (2017) · Bone · doi:10.1016/j.bone.2017.09.008 · Cited by 288
Clinical relevance of sarcopenia in chronic kidney disease
Moorthi, R. N., & Avin, K. G. (2017) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0000000000000318 · Cited by 269
The role of exercise-induced myokines in regulating metabolism
Huh, J. Y. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0994-y · Cited by 242
Metadata
- Authors
- WOODHOUSE, L., GANDHI, R., WARDEN, S. J., POIRAUDEAU, S., MYERS, S. L., BENSON, C. T., HU, L., AHMAD, Q. I., LINNEMEIER, P., GOMEZ, E. V., & BENICHOU, O.
- Venue
- The Journal of Frailty & Aging
- Publisher
- Elsevier BV
- Published
- 2016
- Volume
- 5
- Issue
- 1
- Pages
- 1-9
- ISSN
- 2260-1341 (ISSN-L)
- 2273-4309
- OpenAlex
- W2409962461
- Cited by
- 80
- References
- 0
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A PHASE 2 RANDOMIZED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MYOSTATIN ANTIBODY LY2495655 VERSUS PLACEBO IN PATIENTS UNDERGOING ELECTIVE TOTAL HIP ARTHROPLASTY. https://app.cochat.ai/papers/10.14283/jfa.2016.81
- The paper
- WOODHOUSE, L., GANDHI, R., WARDEN, S. J., POIRAUDEAU, S., MYERS, S. L., BENSON, C. T., HU, L., AHMAD, Q. I., LINNEMEIER, P., GOMEZ, E. V., & BENICHOU, O. (2016). A PHASE 2 RANDOMIZED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MYOSTATIN ANTIBODY LY2495655 VERSUS PLACEBO IN PATIENTS UNDERGOING ELECTIVE TOTAL HIP ARTHROPLASTY. The Journal of Frailty & Aging. https://doi.org/10.14283/jfa.2016.81
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.